



RECEIVED

JUN 19 2002

TECH CENTER 1600/2900

1625
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: R.K. Bakshi, et al.
Serial No.: 09/990,499 (Case No. 20385YDA)

Filed: November 21, 2001

For: SUBSTITUTED PIPERIDINES AS
MELANOCORTIN-4 RECEPTOR
AGONISTS

Art Unit:
1625

Examiner:
D. M. Seaman

4/2
5/9/02
H-02

COPY OF PAPERS
ORIGINALLY FILED

Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT UNDER 37 C.F.R. 1.111

Sir:

In response to the Official Action dated March 11, 2002, for which a response is due by June 11, 2002, please consider the following arguments and remarks which are deemed to place the application in condition for allowance.

IN THE CLAIMS:

Cancel Claims 1-38 without prejudice.

Insert new Claims 39-75 as follows:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., INC.

By Danesh Bhowmik Date 6/4/2002

39. (New) A method of treating erectile dysfunction in a male subject which comprises administering to the subject in need thereof a therapeutically effective amount of a compound which is a human melanocortin-4 receptor (MC-4R) agonist wherein the binding of the compound to the human MC-4R is characterized by an IC₅₀ less than 30 nanomolar (nM)